I N T I M A C Y A N D S E X U A L I T Y I N L A T E R L I F E
|
|
- Christiana Page
- 6 years ago
- Views:
Transcription
1 I N T I M A C Y A N D S E X U A L I T Y I N L A T E R L I F E
2 DESPITE THE COMMON COMPLAINT, EACH PATIENT COMES AS AN INDIVIDUAL, WITH UNIQUE EXPECTATIONS My special interest Counseling patients prior to major pelvic surgery with high risk of erectile dysfunction Supporting patients through their journey to regain their sexual function after surgery penile rehabilitation
3 A DOCTOR S PERSPECTIVE ERECTILE DYSFUNCTION Definition: Persistent inability to attain and maintain an erection sufficient to permit satisfactory sexual performance But.. What does this actually mean to the patient? Does it get hard, and stay hard enough to satisfy the sexual needs of the patient (and the partner)
4 PATIENTS RELUCTANT TO TALK TO THEIR DOCTORS ABOUT ED WHY? 71% 68% 44% Patients believe ED would not be recognized as a medical problem Patients fear that discussing sexuality may embarrass their doctors 44% of men attending urologists have ED but fail to mention it - most are too embarrassed Marwick C. JAMA 1999;281:
5 ASIAN PREVALENCE OF ED Author/Year Region Prevalence of ED (age group in years) Khoo et al./ Malaysia 70.1% in men >50 years of age Quek et al./ Malaysia 41.6% in men >20 years of age Li et al./ Malaysia 59% in men of years of age Masumori et al./ Japan 15% (40 49), 23% (50 59), 39% (60 69), 71% (70 79) Kongkanand et al. / Thailand 7% (40 49), 22% (50 59), 49% (60 69) Moreira et al. / Korea 32% in men of years 1.Khoo et al. J Sex Med 2008;5: Quek et al., J Sex Med 2008;5: Li, et al. BJU Int 2005;96: Masumori et al., Urology 1999;54: Konkanad A. Int J Androl 2000;23: Moreira et al., J Sex Med 2006;3:
6 Predicted increase In prevalence of ED by 2025 North America Europe Asia South & Central America and the Caribbean Africa Oceania Worldwide prevalence will increase from 152 million men in 1995 to 322 million men in Aytac IA et al. BJU Int 1999; 84:
7 Prevalence of co-morbidities (%) ED is linked to serious health problems! No ED ED N=23, *P< High blood pressure Heart trouble or angina* High cholesterol Diabetes* Depression* Any of these Rosen RC, Fisher WA, Eardley I, et al. The multinational men s attitudes to life events and sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Cur Med Res Opin. 2004;20(5):
8 ERECTILE DYSFUNCTION: NARROWING OF BLOOD VESSELS ED manifests earlier than cardiovascular disease because the smaller penile arteries reach critical narrowing, with insufficient blood flow, earlier than larger vessels (Threshold for symptom development is 50% lumen.) Early Late Penile artery 1-2 mm ED Coronary artery 3-4 mm Angina/infarction Carotid artery 5-7 mm Stroke Femoral artery 6-8 mm Claudication Montorsi P, Ravagnani PM, Galli S, et al. The artery size hypothesis: a macrovascular link between erectile dysfunction and coronary artery disease. Am J Cardiol. 2005;96(suppl):19M 23M. 8
9 ERECTILE DYSFUNCTION Cardiovascular risk Men with organic ED should have their cardiac risk factors addressed ED is significantly associated with cardiovascular risk factors. These include: hypertension raised cholesterol (hyperlipidaemia) diabetes smoking There is a degree of cardiac risk associated with sexual activity, so it is crucial to assess the CV risk The risk is small (~1% for myocardial infarction) and low compared with many other risks most patients will encounter (e.g. watching football) Jackson G, Rosen RC, Kloner RA, et al. The Second Princeton Consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. J Sex Med. 2006;3:28-36; Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study. J Urol. 1994;151(1):54-61; Chi JS, Kloner RA. Stress and myocardial infarction. Heart. 2003;89:
10 ERECTILE DYSFUNCTION Princeton II evaluation algorithm Jackson G, Rosen RC, Kloner RA, et al. The Second Princeton Consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. J Sex Med. 2006;3:
11 ERECTILE DYSFUNCTION Diabetes 20-85% of men with diabetes suffer from ED (ranging from mild to complete) ED was three times more common in diabetic men vs nondiabetic men ED occurs earlier in men with diabetes compared with men who do not have diabetes The risk of ED increases: The longer diabetes is present If the condition is inadequately controlled (raised blood glucose and HbA 1C ) 11
12 ERECTILE DYSFUNCTION Prostate Men with enlarged prostates can also suffer from erection problems ED is underdiagnosed in patients consulting urologists for benign prostatic hyperplasia ED is very often seen after radical prostatectomy for prostate cancer 44-75% of patients Hosel CE, Woll EM, Burkart M, et al. Erectile dysfunction (ED) is prevalent, bothersome and underdiagnosed in patients consulting urologists for benign prostatic syndrome (BPS). Eur Urol. 2005;47: ; Taher A. Erectile dysfunction after transurethral resection of the prostate: incidence and risk factors. World J Urol. 2004;22: ; Matthew AG, Goldman A, Trachtenberg J, et al. Sexual dysfunction after radical prostatectomy prevalence, treatments, restricted use of treatments and distress. J Urol. 2005;174: ; Brown MW, Brooks JP, Albert PS, et al. An analysis of erectile function after intensity modulated radiation therapy for localized prostate carcinoma. Prostate Cancer Prostatic Dis. 2007;10:
13 ERECTILE DYSFUNCTION Impact on quality of life Men with ED experience low self-esteem, diminished confidence, and relationship problems Partners often have feelings of rejection, unattractiveness, and guilt Improvements in erection hardness with ED oral treatment have shown to improve satisfaction with sex life, love and romance, and overall health An awareness of the impact of ED on quality of life (QoL) can help health care providers: Empathize and communicate effectively with sufferers Appreciate the value of appropriate treatment Althof SE. Quality of life and erectile dysfuntion. Urology. 2002;59: ; Cappelleri JC, Bell SS, Althof SE, et al. Comparison between sildenafil-treated subjects with erectile dysfunction and control subjects on the self-esteem and relationship questionnaire. J Sex Med. 2006;3: ; Speckens AEM, Hengeveld MW, Nijeholt GL, et al. Psychosexual functioning of partners of men with presumed non-organic erectile dysfunction: cause or consequence of the disorder? Arch Sex Behav. 1995;24(2): ; Montorsi F, Padma-Nathan H, Glina S. Erectile function and assessments of erection hardness correlate positively with measures of emotional well-being, sexual satisfaction, and treatment satisfaction in men with erectile dysfunction treated with sildenafil citrate(viagra ). Urology. 2006;68(suppl 3A):
14 DIAGNOSIS AND TREATMENT OF ERECTILE DYSFUNCTION F E B R U A R Y 2 6,
15 DIAGNOSIS AND TREATMENT OF ED Diagnosis of ED Basic workup includes: Medical history Psychological history Sexual history Physical examination Laboratory tests Medical and psychological histories should be taken for both patients and their partners Wespes E, Amar E, Eardley I, et al. Erectile dysfunction and premature ejaculation. Guidelines on Male Sexual Dysfunction
16 DIAGNOSIS AND TREATMENT OF ED Patient with erectile dysfunction (self-reported) Medical and psychosexual history (use of validated instruments, eg IIEF) Identify other than ED sexual problems Identify common causes of ED Identify reversible risk factors for ED Assess psychosocial status Focused physical examination Penile deformities Prostatic disease Signs of hypogonadism Cardiovascular and neurological issues Laboratory tests Glucose-lipid profile (if not assessed in the past 12 months) Total testosterone (morning sample) If available: bio-available or free testosterone (instead of total) Wespes E, Amar E, Eardley I, et al. Erectile dysfunction and premature ejaculation. Guidelines on Male Sexual Dysfunction. 2012; Hatzimouratidis K, Amar E, Eardley I, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol. 2010;57:
17 DIAGNOSIS AND TREATMENT OF ED Erection Hardness Score The EHS is a robust, validated, single-item patient-reported outcome for evaluating erection hardness Improvements in erection hardness have correlated with a restoration of confidence in the ED patient You can educate sufferers to use the EHS to assess the severity of their ED An expert panel defined the maximum score 4 as the main goal in the treatment of ED EHS 1 EHS 2 EHS 3 EHS 4 Penis is larger but not hard Penis is hard, but not hard enough for penetration Penis is hard enough for penetration, but not completely hard Penis is completely hard and fully rigid Mulhall J, Althof SE, Brock GB, et al. Erectile dysfunction: monitoring response to treatment in clinical practice recommendations of an international study panel. J Sex Med. 2007;4: ; Mulhall JP, Goldstein I, Bushmakin AG, et al. Validation of the erection hardness score. J Sex Med. 2007;4:
18 Clinical approaches to treatment of ED F O O T N O T E S 18
19 DIAGNOSIS AND TREATMENT OF ED First-line treatment: Oral treatment PDE5 inhibitors PDE5 inhibitors are recommended as the preferred pharmacotherapy for ED PDE5i is a class of vasodilators that work on the nitric oxide-cgmp mechanism to help restore natural erectile function in the presence of sexual stimulation Efficacy is defined by rigidity sufficient for vaginal penetration Sildenafil citrate (Viagra) was the first licensed oral medication for ED, receiving marketing authorization in 1998 Vardenafil (Levitra) and tadalafil (Cialis) received marketing authorization in 2003 Wespes E, Amar E, Hatzichristou D, et al. EAU Guidelines on erectile dysfunction: an update. Eur Urol. 2006;49: ; Wright PJ. Comparison of phosphodiesterase type 5 (PDE5) inhibitors. Int J Clin Pract. 2006;60: ; Mulhall J, Althof SE, Brock GB, et al. Erectile dysfunction: monitoring response to treatment in clinical practice recommendations of an international study panel. J Sex Med. 2007;4: ; Rosen RC, Kostis JB. Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am J Cardiol. 2003;92(suppl):9M-18M; Wespes E, Amar E, Eardley I, et al. Erectile dysfunction and premature ejaculation. Guidelines on Male Sexual Dysfunction
20 Efficacy evaluation during placebo-controlled studies D A T E 20
21 Increase from baseline SILDENAFIL EFFICACY 24-week dose-response study: Ability to achieve erection Percent increase from baseline in response to IIEF Q3: When you attempted sexual intercourse, how often were you able to penetrate your partner? Placebo Sildenafil Sildenafil Sildenafil n= mg n=96 50 mg n= mg n=101 P< % = End point: 4.00, baseline: % = End point: 3.50, baseline: % = End point: 3.20, baseline: % = End point: 2.20, baseline: 2.10 The results were derived from a 24-week, dose-response, placebo-controlled study with 501 patients completing evaluation. Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 1998; 338:
22 Increase from baseline SILDENAFIL EFFICACY 24-week dose-response study: Maintenance of erection Percent increase from baseline in response to IIEF Q4: During sexual intercourse, how often were you able to maintain your erection after you had penetrated your partner? P< % = End point: 3.9, baseline: % = End point: 3.5, baseline: % = End point: 3.1, baseline: % = End point: 2.1, baseline: Placebo Sildenafil Sildenafil Sildenafil n= mg n=96 50 mg n= mg n=101 The results were derived from a 24-week, dose-response, placebo-controlled study with 501 patients completing evaluation. Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 1998; 338:
23 SILDENAFIL EFFICACY Discontinuations Variable 24-week dose-response study number of men (percent) Placebo (n=216) Sildenafil 25 mg(n=102) Sildenafil 50 mg(n=107) Sildenafil 100 mg(n=107) Reason for discontinuation All causes Treatment-related adverse effect Insufficient response Other* 36 (17) 1 (<1) 11 (5) 24 (11) 15 (15) 1 (1) 3 (3) 11 (11) 8 (7) 1 (1) 2 (2) 5 (5) 8 (7) 2 (2) 0 6 (6) Adverse effect** Headache Flushing Dyspepsia Rhinitis Visual disturbance*** 14 (6) 3 (1) 3 (1) 4 (2) 1 (<1) 14 (14) 13 (13) 3 (3) 1 (1) 2 (2) 23 (21) 29 (27) 12 (11) 3 (3) 6 (6) 32 (30) 21 (20) 17 (16) 12 (11) 10 (9) *Other reasons for discontinuation included protocol violations, not returning for follow-up, adverse effects not related to treatment, withdrawal of consent, and other reasons. **The adverse effects listed are those that occurred in 5% or more of any treatment group. ***The visual disturbances reported were changes in the perception of color hue or brightness. Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 1998; 338:
24 SILDENAFIL EFFICACY 12-week evaluation of sildenafil in the treatment of ED of various etiologies Objective: To determine the efficacy and safety of fixed-dose sildenafil in patients with ED of various etiologies. Study design: 12-week, double-blind, placebo-controlled, fixed-dose study. Patients: 514 men (ages 19 to 79) with ED and co-morbid conditions including genitourinary procedures, essential hypertension, diabetes mellitus, BPH, depression, or ischemic heart disease. Montorsi F, McDermott TED, Morgan R, et al. Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectie dysfunction of various etiologies. Urology. 1999;53:
25 SILDENAFIL EFFICACY 12-week evaluation of patient/partner satisfaction with sildenafil in the treatment of ED Objective: To assess the efficacy and safety of sildenafil in men with erectile dysfunction and patient and partner satisfaction with treatment using EDITS. Study design: 12-week, multicenter, double-blind, placebo-controlled, parallel-group, flexible-dose study. Patients: 247 men (ages 31 to 81) with ED and co-morbid conditions including essential hypertension, diabetes, hypercholesterolemia, hyperlipidemia, and prostatic hyperplasia. Lewis R, Bennett CJ, Borkon WD, et al. Patient and partner satisfaction with VIAGRA (sildenafil Citrate) treatment as determined by the erectile dysfunction inventory of treatment satisfaction questionnaire. Urology. 2001; 57:
26 Mean scores SILDENAFIL EFFICACY 12-week fixed-dose study: Patient/partner responses to IIEF questionnaire Mean scores at baseline and at the end of doubleblind treatment Almost always/ always 5 Most times 4 Patient responses to IIEF Q3, Q4, Q7 Baseline Placebo, 12 weeks Sildenafil, 12 weeks * *P<.001 compared with placebo * * Sometimes 3 A few times 2 Almost never/ never 1 Did not attempt 0 Q3 Q4 Q7 Ability to maintain erection Ability to achieve erection Intercourse satisfaction Adapted from Lewis R, Bennett CJ, Borkon WD, et al. Patient and partner satisfaction with VIAGRA (sildenafil Citrate) treatment as determined by the erectile dysfunction inventory of treatment satisfaction questionnaire. Urology. 2001; 57:
27 Mean scores SILDENAFIL EFFICACY 12-week fixed-dose study: Patient/partner responses to IIEF questionnaire Partner responses to IIEF Q1, Q2, Q3 Mean scores at baseline and at the end of doubleblind treatment Almost always/ always 5 Most times 4 Baseline *P<.001 compared with placebo Placebo, 12 weeks Sildenafil, 12 weeks * * Sometimes 3 * A few times 2 Almost never/ never 1 Did not attempt 0 Q1 Q2 Q3 Rating of maintained erections Rating of patient s erections Rating of satisfaction with sexual intercourse Adapted from Lewis R, Bennett CJ, Borkon WD, et al. Patient and partner satisfaction with VIAGRA (sildenafil Citrate) treatment as determined by the erectile dysfunction inventory of treatment satisfaction questionnaire. Urology. 2001; 57:
28 SILDENAFIL EFFICACY Analysis of pooled data from sildenafil double-blind studies in ED patients with co-morbidities Objective: To evaluate findings from 11 double-blind, placebo-controlled, flexible-dose (taken as needed) sildenafil studies. Study design: Four-week baseline period and a 12-week, double-blind, placebocontrolled study. Patient: 2,667 patients (ages 23 to 89) with ED and co-morbid conditions including diabetes, ischemic heart disease, peripheral vascular disease, post-radical prostatectomy, hypertension, depression, or concomitant use of antihypertensive or antidepressant medications. Carson CC, Burnett AL, Levine LA, et al. The efficacy of sildenafil citrate (VIAGRA ) in clinical populations: an update. Urology. 2002; 60(suppl 2B):
29 SILDENAFIL EFFICACY Analysis of pooled data from sildenafil double-blind studies in ED patients with co-morbidities Dosage: Patients were randomized to an initial dose of 50 mg sildenafil or matching placebo. Dose could be increased to 100 mg or decreased to 25 mg based on efficacy or tolerability. Efficacy parameters for the 11 pooled studies: Patients were asked to respond to question 3 (achieving an erection) and question 4 (maintaining erections) of the IIEF questionnaire. A global efficacy question (whether treatment improved erections) was asked at the end of treatment. In 6 of the 11 studies, patients were asked to keep an event log of sexual activity. Carson CC, Burnett AL, Levine LA, et al. The efficacy of sildenafil citrate (VIAGRA ) in clinical populations: an update. Urology. 2002; 60(suppl 2B):
30 Mean score SILDENAFIL EFFICACY Results from 11 pooled double-blind studies: Patient responses to IIEF Q3 Overall baseline mean score and least squares mean (+) SE scores at end of treatment for IIEF question 3 (ability to achieve erections) 5.0 Baseline Placebo Sildenafil *P< * * * * * 3.8 * * * n= Organic Mixed PsychogenicMild/moderate Severe 2yr 2 to 5 yr > 5 yr ED etiology ED severity ED duration Adapted from Carson CC, Burnett AL, Levine LA, et al. The efficacy of sildenafil citrate (VIAGRA ) in clinical populations: an update. Urology. 2002; 60(suppl 2B):
31 Mean score SILDENAFIL EFFICACY Results from 11 pooled double-blind studies: Patient responses to IIEF Q4 Overall baseline mean score and least squares mean (+) SE scores at end of treatment for IIEF question 4 (ability to maintain erections) Baseline Placebo Sildenafil* * * * * * 3.7* 3.6* *P< * n= Organic Mixed PsychogenicMild/Moderate Severe 2yr 2 to 5 yr > 5 yr ED etiology ED severity ED duration Adapted from Carson CC, Burnett AL, Levine LA, et al. The efficacy of sildenafil citrate (VIAGRA ) in clinical populations: an update. Urology. 2002; 60(suppl 2B):
32 ENDOTRIAL study EVALUATION OF EFFICACY IN THE TREATMENT OF ED AMONG SILDENAFIL, TADALAFIL, AND VARDENAFIL (ENDOTRIAL STUDY) D A T E 32
33 SILDENAFIL EFFICACY Within-subject mean change from baseline for IIEF: International Index of Erectile Function question 15 a Primary outcome showing statistical equivalence for all four PDE5i (Data for IIEF questions 1-5 not shown) ** ** * * * P =< ** P = Vardenafil 20 mg Tadalafil 20 mg Sildenafil 50 mg Sildenafil 100 mg a Question 15: How do you rate your confidence that you could get and keep an erection? A spontaneous, open-label, randomized, multicenter, crossover study. The protocol consisted of a fourweek washout period, followed by an eight-week treatment period. Data for primary efficacy were available for 77 out of 100 patients. Jannini EA, Isidori AM, Gravina GL, et al. The ENDOTRIAL study: spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunctionjsm. J Sex Med. 2009;6:
34 THE TIMING FOR SEX ACCORDING TO MEDICATION Parameter Sildenafil, 100 mg Tadalafil, 20 mg Vardenafil, 20 mg Time to maximum effect hours 2 hours 0.9 hours Half-life of drug hours 17.5 hours 3.9 hours
35 General side effects 35 D A T E
36 SILDENAFIL SAFETY Reported adverse reactions Medically important adverse reactions reported during clinical trials or post-marketing surveillance Very common ( 10% of patients) Uncommon ( 0.1% to <1% of patients) Rare ( 0.01% to <0.1% of patients) Incidence not known* Headache Common ( 1% to <10% of patients) Dizziness Visual disorders Visual color distortion Flushing Nasal congestion Dyspepsia Somnolence Hypoaesthesia Conjunctival disorders Eye disorders Lacrimation disorders Vertigo Tinnitus Vomiting Nausea Dry mouth Palpitations Increased heart rate (by investigation) Tachycardia Skin rash Myalgia Chest pain Fatigue Hypersensitivity reactions Atrial fibrillation Myocardial infarction Cerebrovascular accident Hypertension Hypotension Syncope Sudden deafness Epistaxis Transient ischemic attack Unstable angina Ventricular arrhythmia Sudden cardiac death Seizure Seizure recurrence Non-arteritic anterior ischemic optic neuropathy (NAION) Retinal vascular occlusion Visual field defect Priapism Prolonged erection * Reported through post-marketing surveillance so incidence unknown. VIAGRA Summary of Product Characteristics
37 IMPACT OF TREATMENT ON SELF-ESTEEM AND CONFIDENCE IN THE ED PATIENT Men with ED experience low rates of confidence Treatment with a PDE5 inhibitor has been associated with an increase in self-esteem and confidence in patients with ED From both patient and partner perspectives, satisfaction with ED treatment plays a critical role in maintaining long-term therapy for ED Althof SE. Quality of life and erectile dysfunction. Urology. 2002;59: ; Althof SE, Cappelleri JC, Shpilsky A, et al. Treatment responsiveness of the self-esteem and relationship questionnaire in erectile dysfunction. Urology. 2003;61: ; Althof SE, O'Leary MP, Cappelleri JC, et al. Selfesteem, confidence, and relationships in men treated with sildenafil citrate for erectile dysfunction. J Gen Intern Med. 2006; 21: ; McCabe MP, Conaglen H, Conaglen J, et al. Motivations for seeking treatment for ED: the woman s perspective. Int J Impot Res. 2010;22: ; McCullough AR, Barada JH, Fawzy A, et al. Achieving treatment optimization with sildenafil citrate(viagra ) in patients with erectile dysfunction. Urology. 2002;60(Suppl 2B):
IC351 (tadalafil, Cialis): update on clinical experience
(2002) 14, Suppl 1, S57 S64 ß 2002 Nature Publishing Group All rights reserved 0955-9930/02 $25.00 www.nature.com/ijir IC351 (tadalafil, Cialis): update on clinical experience 1 * 1 Urological practice,
More informationErectile Dysfunction: A Primer for Primary Care Providers
Erectile Dysfunction: A Primer for Primary Care Providers Jeanne Martin, DNP, ANP-BC Objectives 1. Understand the definition, incidence and prevalence of Erectile Dysfunction in the U.S. 2. Understand
More informationErectile Dysfunction. Dr Mampedi Bogoshi
Erectile Dysfunction Dr Mampedi Bogoshi February 26, 2014 1 Erectile Dysfunction What is ED? ED: Erectile dysfunction is defined as the inability to achieve and/or maintain a penile erection sufficient
More informationGUIDELINES ON ERECTILE DYSFUNCTION
GUIDELINES ON ERECTILE DYSFUNCTION (Text updated March 2005) E. Wespes (chairman), E. Amar, D. Hatzichristou, K. Hatzimouratidis, F. Montorsi, J. Pryor, Y. Vardi 88 Erectile Dysfunction Eur Urol 2001;40:97-101
More informationERECTION HARDNESS: A UNIFYING FACTOR FOR DEFINING RESPONSE IN THE TREATMENT OF ERECTILE DYSFUNCTION
ERECTION HARDNESS: A UNIFYING FACTOR FOR DEFINING RESPONSE IN THE TREATMENT OF ERECTILE DYSFUNCTION JOHN P. MULHALL, LAURENCE A. LEVINE, and KLAUS-PETER JÜNEMANN ABSTRACT The extensive sildenafil citrate
More informationfor ED and LUTS/BPH Pierre Sarkis, M.D. Assistant Professor Fellow of the European Board of Urology
Tadalafil 5 mg once daily for ED and LUTS/BPH Pierre Sarkis, M.D. Assistant Professor Fellow of the European Board of Urology Why this conference? Not promotional but educational The pharmacist regularly
More informationWith My Heart, Can or Should I Take Erectile Dysfunction Drugs?
With My Heart, Can or Should I Take Erectile Dysfunction Drugs? Timothy R. Malinowski MD, FACC UMG Carolina Cardiology Consultants Greenville Health System Definition of Erectile Dysfunction 1992 NIH Consensus
More informationGUIDELINES ON ERECTILE DYSFUNCTION
16 GUIDELINES ON ERECTILE DYSFUNCTION E. Wespes (chairman), E. Amar, D. Hatzichristou, Dr. F. Montorsi, J. Pryor, Y. Vardi Eur Urol 2002;41:1-5 1. Background, definition and classification Male erectile
More informationErectile dysfunction: unmet needs
Erectile dysfunction: unmet needs Dimitris Hatzichristou Professor of Urology / Andrology Director, Center for Sexual and Reproductive Health Aristotle University of Thessaloniki, Greece The numbers MMAS
More informationMMM. Topic The use of Tadalafil 5mg daily for the treatment of BPH-LUTS
Dr Tan & Partners MMM Vol. 1 No. 1 Morbidity & Mortality Meeting 14 th November 2014 Introduction Topic The use of Tadalafil 5mg daily for the treatment of BPH-LUTS Tadalafil 5mg daily is a well established
More informationManaging Erectile Dysfunction
Managing Erectile Dysfunction Lewis E. Harpster MD, FACS Urology of Central PA 4/23/16 1 Objectives 1. Review physiologic mechanism of erection 2. Discuss medical management of ED 3. Discuss surgical management
More informationIntroduction. A Benchekroun 1 *, M Faik 1, S Benjelloun 2, S Bennani 2, M El Mrini 2 and A Smires 3
(2003) 15, Suppl 1, S19 S24 & 2003 Nature Publishing Group All rights reserved 0955-9930/03 $25.00 www.nature.com/ijir A baseline-controlled, open-label, flexible dose-escalation study to assess the safety
More informationERECTILE DYSFUNCTION DIAGNOSIS
ERECTILE DYSFUNCTION DIAGNOSIS Head of Andrology and Sexual Medicine Dep.of Urology and Nefrology Hospital Virgen del Rocío ANDROMEDI. Sexual Medicine SEVILLA. SPAIN General Secretary ESSM Natalio Cruz
More informationIntroduction. University, Beachwood, OH, USA; 3 Pfizer Inc, New York, NY, USA ABSTRACT
Blackwell Science, LtdOxford, UKVHEValue in Health1098-3015ISPOR 1098-3015/05? 2005815460Original ArticleEDITS/SEAR AssociationCappelleri et al. Volume 8 Supplement 1 2005 VALUE IN HEALTH Association between
More informationThe efficacy and safety of tadalafil: an update
Original Article C.C. CARSON et al. The efficacy and safety of tadalafil: an update C.C. CARSON, J. RAJFER, I. EARDLEY, S. CARRIER, J.S. DENNE, D.J. WALKER, W. SHEN and W.H. CORDELL Department of Surgery,
More informationOpinion: Yes. PDE-5 inhibitors should be used post radical prostatectomy as erection function rehabilitation?
Difference of opinion Vol. 43 (3): 385-389, May - June, 2017 doi: 10.1590/S1677-5538.IBJU.2017.03.03 PDE-5 inhibitors should be used post radical prostatectomy as erection function rehabilitation? Opinion:
More information/02/ /0 Vol. 168, , October 2002 THE JOURNAL OF UROLOGY
0022-5347/02/1684-1332/0 Vol. 168, 1332 1336, October 2002 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2002 by AMERICAN UROLOGICAL ASSOCIATION, INC. DOI: 10.1097/01.ju.0000028041.27703.da Original
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE. Bulletin 169: Daily Tadalafil (Cialis ) for penile rehabilitation following radical prostactectomy
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE September 2012 Review date: September 2014 Bulletin 169: Daily Tadalafil (Cialis ) for penile rehabilitation following radical prostactectomy JPC Recommendation:
More informationORIGINAL ARTICLE Post-marketing surveillance study of the efficacy and safety of vardenafil among patients with erectile dysfunction in primary care
(2007) 19, 393 397 & 2007 Nature Publishing Group All rights reserved 0955-9930/07 $30.00 www.nature.com/ijir ORIGINAL ARTICLE Post-marketing surveillance study of the efficacy and safety of vardenafil
More informationClinical evaluation of Tentex forte and Himcolin cream in the treatment of functional erectile dysfunction
Medicine Update (2004): 11(9), 47-51 Clinical evaluation of Tentex forte and Himcolin cream in the treatment of functional erectile dysfunction Dr. Roumen Bostandjiev, Ph.D. Founder and Director of Sexology
More informationORIGINAL INVESTIGATION. Sildenafil for Male Erectile Dysfunction
Sildenafil for Male Erectile Dysfunction A Systematic Review and Meta-analysis ORIGINAL INVESTIGATION Howard A. Fink, MD, MPH; Roderick Mac Donald, MS; Indulis R. Rutks, BS; David B. Nelson, PhD; Timothy
More informationDATE BIO# NAME: Last First Middle REFERRING PHYSICIAN NAME: REFERRING PHYSICIAN SPECIALTY (Urologist, Internist, etc.): PRIMARY CARE PHYSICIAN NAME:
DATE BIO# ERECTILE DYSFUNCTION QUESTIONNAIRE NAME: Last First Middle BIRTHDATE: OCCUPATION: REFERRING PHYSICIAN NAME: REFERRING PHYSICIAN SPECIALTY (Urologist, Internist, etc.): PRIMARY CARE PHYSICIAN
More informationEvidence Review for Surrey Prescribing Clinical Network. Treatment: Oral and non-oral combination therapy for erectile dysfunction
Evidence Review for Surrey Prescribing Clinical Network Treatment: Oral and non-oral combination therapy for erectile dysfunction Prepared by: Linda Honey Topic Submitted by: Prescribing Clinical Network
More informationTestosterone and PDE5 inhibitors in the aging male
Testosterone and PDE5 inhibitors in the aging male Francesco Romanelli Department of Experimental Medicine Medical Pathophysiology, Food Science and Endocrinology Section Sapienza University of Rome 3005
More informationErectile dysfunction. By Anas Hindawi Supervised by Dr Khalid AL Sayyid
Erectile dysfunction By Anas Hindawi Supervised by Dr Khalid AL Sayyid ED is the persistent/recurrent inability to attain and/or maintain a penile erection rigid enough for satisfactory sexual intercourse
More informationEAU GUIDELINES ON MALE SEXUAL DYSFUNCTION: Erectile Dysfunction and Premature Ejaculation
EAU GUIDELINES ON MALE SEXUAL DYSFUNCTION: Erectile Dysfunction and Premature Ejaculation (Partial text update March 2015) K. Hatzimouratidis (Chair), F. Giuliano, I. Moncada, A. Muneer, A. Salonia (Vice-chair),
More informationED treatments: PDE5 inhibitors, injections and vacuum devices
ED treatments: PDE5 inhibitors, injections and vacuum devices Martin Steggall Clinical Nurse Specialist (Erectile Dysfunction and Premature Ejaculation) Barts Health NHS Trust; Associate Dean, Director
More informationTITLE: Phosphodiesterase 5 Inhibitors: A Review of the Clinical Effectiveness and Cost- Effectiveness
TITLE: Phosphodiesterase 5 Inhibitors: A Review of the Clinical Effectiveness and Cost- Effectiveness DATE: 15 July 2010 CONTEXT AND POLICY ISSUES: Erectile dysfunction is the most commonly encountered
More informationErectile Dysfunction Medical Treatment
1 Erectile Dysfunction Medical Treatment Alireza Ghoreifi Assistant of Urology Mashhad University of Medical Sciences March 2012 2 Treatment of ED Unknown cases of ED First-line therapy Second-line therapy
More informationMedical Management of Erectile Dysfunction. Maarten Albersen MD PhD University Hospitals Leuven,
Medical Management of Erectile Dysfunction Maarten Albersen MD PhD University Hospitals Leuven, Belgium @maartenalbersen COI Consultancy/speaker for: Ferring, Sanofi, BSCI, Coloplast, Pfizer, Lilly, Menarini,
More informationDaily vs. on-demand PDE-5 inhibitors for management of erectile dysfunction following treatment for prostate cancer
Daily vs. on-demand PDE-5 inhibitors for management of erectile dysfunction following treatment for prostate cancer Lead author: Nancy Kane Regional Drug & Therapeutics Centre (Newcastle) February 2018
More information/04/ /0 Reprinted from Vol. 172, , August 2004 THE JOURNAL OF UROLOGY
0022-5347/04/1722-0658/0 Reprinted from Vol. 172, 658 663, August 2004 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2004 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000132389.97804.d7
More informationClinical Study Synopsis
Clinical Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website or on the website www.clinicalstudyresults.org hosted by the Pharmaceutical Research and
More informationERECTILE DYSFUNCTION PREMATURE EJACULATION. David Goldmeier
ERECTILE DYSFUNCTION PREMATURE EJACULATION David Goldmeier d.goldmeier@nhs.net LEARNING OBJECTIVES Management of erectile dysfunction and premature ejaculation in General Practice Discussion and consideration
More informationGUIDELINES ON MALE SEXUAL DYSFUNCTION: Erectile Dysfunction and Premature Ejaculation
GUIDELINES ON MALE SEXUAL DYSFUNCTION: Erectile Dysfunction and Premature Ejaculation (Text update March 2009) E. Wespes, E. Amar, I. Eardley, F. Giuliano, D. Hatzichristou, K. Hatzimouratidis, F. Montorsi,
More informationClinical Trial Study Synopsis
Clinical Trial Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency
More information, David Stultz, MD. Erectile Dysfunction. David Stultz, MD September 10, 2001
Erectile Dysfunction David Stultz, MD September 10, 2001 Case Presentation A 66 year old male presents to your office requesting Viagra. He states that for the past year he has had difficulty forming
More informationOnset and duration of action of sildena l citrate for the treatment of erectile dysfunction
Onset and duration of action of sildena l citrate for the treatment of erectile dysfunction Ian Eardley, 1 Peter Ellis, 2 Mitradev Boolell 2 & Maria Wulff 2 1 Department of Urology, St James University
More informationCentral hemodynamics and prediction of cardiovascular events in patients with erectile dysfunction
Central hemodynamics and prediction of cardiovascular events in patients with erectile dysfunction N.Skliros, N.Ioakeimidis, D.Terentes-Printzios, C.Vlachopoulos Cardiovascular Diseases and Sexual Health
More informationIan Eardley Department of Urology, Leeds Teaching Hospital Trust
Ian Eardley Department of Urology, Leeds Teaching Hospital Trust Assessment of the man with ED Medical therapy for man with ED What to do when pills fail Sexual stimulus Neural pathways Neurotransmitter
More informationSex and the prostate. Before starting treatment. WHO declaration - sexual health 05/12/2013
Sex and the prostate Lorraine Grover Psychosexual nurse specialist The London Clinic and The Prostate Centre, London. BMI Shelburne Hospital, Bucks. National Institute for Health and Clinical Excellence
More informationClinical Trial Study Synopsis
Clinical Trial Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency
More information/03/ /0 Vol. 170, , July 2003 THE JOURNAL OF UROLOGY. Printed in U.S.A. Copyright 2003 by AMERICAN UROLOGICAL ASSOCIATION
0022-5347/03/1701-0159/0 Vol. 170, 159 163, July 2003 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2003 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000072524.82345.6d COMPARISON OF SATISFACTION
More informationavanafil 50mg, 100mg, 200mg tablets (Spedra ) SMC No. (980/14) A. Menarini Farmaceutica Internazionale SRL.
avanafil 50mg, 100mg, 200mg tablets (Spedra ) SMC No. (980/14) A. Menarini Farmaceutica Internazionale SRL. 07 August 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationUp to 85 Percent of Men Achieved Significantly Improved Erections
Corporate Investor Relations First Release of Vardenafil Phase III Pivotal Study Data: Up to 85 Percent of Men Achieved Significantly Improved Erections Additional Phase III Data Show Significant Improvement
More informationPerceptions and opinions of men and women on a man s sexual confidence and its relationship to ED: results of the European Sexual Confidence Survey
International Journal of Impotence Research (2012) 1 -- 8 All rights reserved 0955-9930/12 www.nature.com/ijir ORIGINAL ARTICLE Perceptions and opinions of men and women on a man s sexual confidence and
More informationMALE SEXUAL DYSFUNCTION. Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara
MALE SEXUAL DYSFUNCTION Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara DEFINITION The inability to achieve a satisfactory sexual relationship May involve : - inadequacy
More informationPhosphodiesterase Type 5 Inhibitors Quantity Limit Program Summary
Phosphodiesterase Type 5 Inhibitors Quantity Limit Program Summary FDA APPROVED INDICATIONS AND DOSAGE 1-4,23 Agent FDA Approved Dosage and Administration Indication Cialis (tadalafil) (ED) ED; As needed:
More informationClinical Trial Study Synopsis
Clinical Trial Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency
More informationAn analysis of treatment preferences and sexual quality of life outcomes in female partners of Chinese men with erectile dysfunction
Erectile Dysfunction Open Access ORIGINAL ARTICLE (2016) 18, 773 779 2016 AJA, SIMM & SJTU. All rights reserved 1008-682X www.asiaandro.com; www.ajandrology.com An analysis of treatment ences and sexual
More informationOriginal Article Effect of sildenafil on erectile dysfunction and improvement in the quality of sexual life in China: a multi-center study
Int J Clin Exp Med 2015;8(7):11539-11543 www.ijcem.com /ISSN:1940-5901/IJCEM0010305 Original Article Effect of sildenafil on erectile dysfunction and improvement in the quality of sexual life in China:
More informationAbout Erectile Dysfunction. Causes, self-test and treatment
About Erectile Dysfunction Causes, self-test and treatment 2015 One Way S.r.l. All rights reserved. Gift copy for physicians. Illustrated by Davide Ceccon With an unrestricted grant from Recordati About
More informationPackage leaflet: Information for the user. Tadalafil Sigillata 20 mg film-coated tablets. tadalafil
Package leaflet: Information for the user Tadalafil Sigillata 20 mg film-coated tablets tadalafil Read all of this leaflet carefully before you start taking this medicine because it contains important
More informationLONG-TERM EFFECT OF SILDENAFIL CITRATE ON ERECTILE DYSFUNCTION AFTER RADICAL PROSTATECTOMY: 3-YEAR FOLLOW-UP
ADULT UROLOGY LONG-TERM EFFECT OF SILDENAFIL CITRATE ON ERECTILE DYSFUNCTION AFTER RADICAL PROSTATECTOMY: 3-YEAR FOLLOW-UP RUPESH RAINA, MILTON M. LAKIN, ASHOK AGARWAL, RAKESH SHARMA, KUSH K. GOYAL, DROGO
More informationNHS Dumfries & Galloway Erectile Dysfunction Audit October 2010
Title of Project: NHS Dumfries & Galloway Erectile Dysfunction Audit October 2010 1 Reason for the review 1. To clarify the indications for erectile dysfunction. 2. To prescribe the formulary choice vardenafil
More informationErectile Dysfunction Case Study 2. Medical Student Case-Based Learning
Erectile Dysfunction Case Study 2 Medical Student Case-Based Learning The Case of Mr. Power s Limp Mojo Mr. Powers develops erectile dysfunction after his radical prostatectomy for prostate cancer. You
More informationDRAFT COPY PERSONAL USE ONLY
Psychological, social, and behavioural benefits for men following effective erectile dysfunction (ED) treatment: men who enjoy better sex experience improved psychological well-being John Dean, Bert-Jan
More informationErectile Dysfunction; It s Not Just About Sex
Erectile Dysfunction; It s Not Just About Sex Disclosures Conflict of interest: I am not paid by Boston Scientific but once in a while they buy me a tasty meal. I do routinely use their products without
More informationErectile dysfunction (ED) is a common male sexual. Clinical Guidelines
Clinical Guidelines Annals of Internal Medicine Oral Phosphodiesterase-5 Inhibitors and Hormonal Treatments for Erectile Dysfunction: A Systematic Review and Meta-analysis Alexander Tsertsvadze, MD, MSc;
More informationOverview. Urology Dine and Learn: Erectile Dysfunction & Benign Prostatic Hyperplasia. Iain McAuley September 15, 2014
Urology Dine and Learn: Erectile Dysfunction & Benign Prostatic Hyperplasia Iain McAuley September 15, 2014 Overview Review of the most recent guidelines for ED and BPH ED Guidelines CUA 2006 AUA 2011
More informationERECTILE DYSFUNCTION. Prof. Khan Abul Kalam Azad. Head, Department of Medicine, Dhaka Medical College President, Bangladesh Society of Medicine
ERECTILE DYSFUNCTION Prof. Khan Abul Kalam Azad Head, Department of Medicine, Dhaka Medical College President, Bangladesh Society of Medicine Bangladesh Society of Medicine Department of Medicine Dhaka
More informationBPH: a present and future perspective on health impact
BPH: a present and future perspective on health impact Burden of disease in men with moderate LUTS Dalibor Pacík This presentation is financially supported by GlaxoSmithKline. CZ/DUTT/0019/12 Men with
More informationCanadian Undergraduate Urology Curriculum (CanUUC): Erectile Dysfunction
Canadian Undergraduate Urology Curriculum (CanUUC): Erectile Dysfunction Last reviewed July 2014 Objectives 1. Define erectile dysfunction 2. List and classify the risk factors for erectile dysfunction
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationCharacteristics of patients with erectile dysfunction in a family physician-led erectile dysfunction clinic: Retrospective case series
Family Medicine and Community Health Case Study Characteristics of patients with erectile dysfunction in a family physician-led erectile dysfunction clinic: Retrospective case series Lap Kin Chiang, Cheuk-Wai
More informationSexual problems in the ageing male: ED
Sexual problems in the ageing male: ED Prism IV September 25-26 Bruges, Belgium Dr. HHJ Leliefeld and Prof. FMJ Debruyne, urologists The Netherlands Erectile disfunction Definition & Prevalence The erectile
More information13-Oct-15 ERECTILE DYSFUNCTION. Urology Subdepartement dr. Mintohardjo Naval Hospital dr. Isdiyanto Septiadi, Sp.U
ERECTILE DYSFUNCTION Urology Subdepartement dr. Mintohardjo Naval Hospital dr. Isdiyanto Septiadi, Sp.U 1 2 3 So what is impotence or erectile dysfunction..? The persistent inability to achieve or maintain
More informationTreatment Strategy for Non-Responders to Tadalafil and Vardenafil: A Real-Life Study
european urology 50 (2006) 126 133 available at www.sciencedirect.com journal homepage: www.europeanurology.com Sexual Medicine Treatment Strategy for Non-Responders to Tadalafil and Vardenafil: A Real-Life
More informationDirect comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta analysis
Int Urol Nephrol (2017) 49:1731 1740 DOI 10.1007/s11255-017-1644-5 UROLOGY - ORIGINAL PAPER Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review
More informationReview Article Penile Rehabilitation Therapy with PDE-V Inhibitors Following Radical Prostatectomy: Proceed with Caution
Advances in Urology Volume 2009, Article ID 852437, 4 pages doi:10.1155/2009/852437 Review Article Penile Rehabilitation Therapy with PDE-V Inhibitors Following Radical Prostatectomy: Proceed with Caution
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: erectile_dysfunction 01/01/2019 n/a 01/01/2020 01/01/2019 Policy Effective April 1, 2019 Description of Procedure
More informationDiagnosis and management of sexual dysfunction. Dr Chris Simpson Consultant Psychiatrist
Diagnosis and management of sexual dysfunction Dr Chris Simpson Consultant Psychiatrist What are we talking about? Male Erectile dysfunction Premature ejaculation Delayed ejaculation Sexual aversion Paraphilia
More informationSYED TABREZ ALI Department of Physiology, Faculty of Medicine P.O. Box 7607, Umm-Al-Qura University, Makkah, Saudi Arabia
EFFECTIVENESS OF SILDENAFIL CITRATE (VIAGRA TM ) AND TADALAFIL (CIALIS TM ) ON SEXUAL RESPONSES IN SAUDI MEN WITH ERECTILE DYSFUNCTION IN ROUTINE CLINICAL PRACTICE SYED TABREZ ALI Department of Physiology,
More informationPenile Rehabilitation after Radical Prostatectomy
Penile Rehabilitation after Radical Prostatectomy The PRO Position John P. Mulhall MD MSc FECSM FACS Director, Sexual & Reproductive Medicine Program Urology Service Memorial Sloan Kettering Cancer Center
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Immediate release tablets 1 mg, 2 mg, 4 mg and 8 mg (IR) Date of FAR:
Core Safety Profile Active substance: Doxazosin Pharmaceutical form(s)/strength: Immediate release tablets 1 mg, 2 mg, 4 mg and 8 mg (IR) P - RMS: DK/H/PSUR/0004/002 Date of FAR: 12.12.2011 4.3 Contraindications
More informationChronic Daily Administration of Vardenafil in Erectile Dysfunction Patients Has No Impact on Semen Parameters or on Sex Hormones Levels
Australian Journal of Basic and Applied Sciences, 2(3): 779-784, 2008 ISSN 1991-8178 Chronic Daily Administration of Vardenafil in Erectile Dysfunction Patients Has No Impact on Semen Parameters or on
More informationPackage leaflet: Information for the user. Tadalafil Sigillata 5 mg film-coated tablets. tadalafil
Package leaflet: Information for the user Tadalafil Sigillata 5 mg film-coated tablets tadalafil Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationMedicines Q&As. Date prepared: November 2016
Q&A 128.3 What is the rationale and evidence for the use of phosphodiesterase-5 inhibitors as supportive therapy to rehabilitate Erectile Function after nerve sparing radical prostatectomy? Summary Prepared
More informationLow Energy Shockwaves for the Treatment of Erectile Dysfunction Y. Vardi, B. Appel, I Gruenwald
Low Energy Shockwaves for the Treatment of Erectile Dysfunction Y. Vardi, B. Appel, I Gruenwald Neuro-Urology Unit, Rambam Medical Center & the Technion Faculty of Medicine Haifa, Israel 3 crucial questions
More informationSee available DOSAGES and PACKAGES. View prices
See available DOSAGES and PACKAGES View prices Levitra Generic SUMMARY OF PRODUCT CHARACTERISTICS NAME OF THE MEDICINAL PRODUCT Levitra Generic film-coated tablets User Information Levitra Generic orodispersible
More informationErectile Dysfunction Prior Authorization with Quantity Limit Criteria Program Summary
Prior Authorization with Quantity Limit Criteria Program Summary Objective The intent of the prior authorization (PA) program for (ED) is to ensure appropriate selection of patients for treatment according
More informationLong-term efficacy and compliance of intracorporeal (IC) injection for erectile dysfunction following radical prostatectomy: SHIM (IIEF-5) analysis
(2003) 15, 318 322 & 2003 Nature Publishing Group All rights reserved 0955-9930/03 $25.00 www.nature.com/ijir Long-term efficacy and compliance of intracorporeal (IC) injection for erectile dysfunction
More informationPenile rehabilitation after radical prostatectomy: patients attitude and feasibility in China
Original Article Penile rehabilitation after radical prostatectomy: patients attitude and feasibility in China Yi-Jun Shen 1,2, Jian Li 1,2, Ding-Wei Ye 1,2 1 Department of Urology, Fudan University Shanghai
More informationThe use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction
(2002) 14, 245 250 ß 2002 Nature Publishing Group All rights reserved 0955-9930/02 $25.00 www.nature.com/ijir The use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic
More informationPenile Implant Should be Offered Early
Penile Implant Should be Offered Early Landon Trost, MD Assistant Professor in Urology Mayo Clinic, Rochester, MN SMSNA AUA May 16 th, 2015 2013 MFMER slide-1 Clear Indications for Penile Implants Men
More informationPackage leaflet: information for the user. Sildenafil 25 mg, 50 mg and 100 mg film-coated tablets Sildenafil
Package leaflet: information for the user Sildenafil 25 mg, 50 mg and 100 mg film-coated tablets Sildenafil Read all of this leaflet carefully before you start taking this medicine because it contains
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT VIAGRA 25 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 25 mg of sildenafil (as citrate)
More informationPrevalence of anxiety and depressive symptoms in men with erectile dysfunction
Prevalence of anxiety and depressive symptoms in men with erectile dysfunction K Pankhurst, MB ChB G Joubert, BA, MSc P J Pretorius, MB ChB, MMed (Psych) Departments of Psychiatry and Biostatistics, University
More informationManaging the Patient with Erectile Dysfunction: What Would You Do?
Managing the Patient with Erectile Dysfunction: What Would You Do? Florida A & M University College of Pharmacy and Pharmaceutical Sciences 42 nd Annual Clinical Symposium Wayne A. Sampson, M.D. Cross
More informationEfficacy and Safety of Linear Focused Shockwaves for Erectile Dysfunction (RENOVA) A Second Generation Technology
Efficacy and Safety of Linear Focused Shockwaves for Erectile Dysfunction (RENOVA) A Second Generation Technology Y. Reisman, MD, PhD. 1, A. Hind, MD. 2, A. Varaneckas, MD. 3, I. Motil, MD. 4 1 Men's Health
More informationJan Farrell. Nurse Consultant Urology Department of Urology Rotherham General Hospital NHS FT
Jan Farrell Nurse Consultant Urology Department of Urology Rotherham General Hospital NHS FT Aims of session To promote discussion / interaction Opportunity to discuss with peers Promote learning / share
More informationMinimal Clinically Important Differences in the Erectile Function Domain of the International Index of Erectile Function Scale
EUROPEAN UROLOGY 60 (2011) 1010 1016 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Sexual Medicine Editorial by Andrea Salonia on pp. 1017 1019 of this
More informationPharmacokinetics, Pharmacodynamics, and. Sussman Phosphodiesterase Type 5 Inhibitors
Clinical evidence in men with erectile dysfunction (ED) shows that the phosphodiesterase type 5 (PDE5) inhibitors sildenafil citrate, tadalafil, and vardenafil hydrochloride have favorable safety and efficacy
More informationPackage leaflet: Information for the patient. Tadalafil Mylan 5 mg film-coated tablets Tadalafil
PACKAGE LEAFLET 1 Package leaflet: Information for the patient Tadalafil Mylan 5 mg film-coated tablets Tadalafil Read all of this leaflet carefully before you start taking this medicine because it contains
More informationPartner Satisfaction and Successful Treatment Outcomes for Men with Erectile Dysfunction (ED)
european urology supplements 5 (2006) 779 785 available at www.sciencedirect.com journal homepage: www.europeanurology.com Partner Satisfaction and Successful Treatment Outcomes for Men with Erectile Dysfunction
More informationSandoz Ltd Sildenafil 25 mg Tablets PL 04416/1297
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Sildenafil 25 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Sildenafil 25 mg tablets Each tablet contains 25 mg of sildenafil
More informationCARDIOVASCULAR SAFETY OF SILDENAFIL CITRATE (VIAGRA ): AN UPDATED PERSPECTIVE
CARDIOVASCULAR SAFETY OF SILDENAFIL CITRATE (VIAGRA ): AN UPDATED PERSPECTIVE GRAHAM JACKSON, PIERO MONTORSI, AND MELVIN D. CHEITLIN ABSTRACT citrate (Viagra ; Pfizer Inc, New York, NY) relaxes vascular
More informationIs This Really a Fair Debate? 2013 MFMER slide-2
Sex Rehab after Radical Prostatectomy: Is it Really Justified? Con Position Landon Trost, MD Assistant Professor of Urology Mayo Clinic, Rochester, MN ISSM 16 th World Meeting on Sexual Medicine October
More informationPackage leaflet: Information for the user. Tadalafil 5 mg film-coated tablets. tadalafil
Package leaflet: Information for the user Tadalafil 5 mg film-coated tablets tadalafil Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationLabeled Uses: Treatment of erectile dysfunction (impotence) 1,2,3, min hr
Brand Name: Stendra Generic Name: avanafil Manufacturer: Vivus, Inc. 1 Drug Class: Phosphodiesterase-5 Enzyme Inhibitor 1,2,3,4 Uses: Labeled Uses: Treatment of erectile dysfunction (impotence) 1,2,3,4
More information